PD-Rx Pharmaceuticals, Inc. (PDRX)
OTCMKTS · Delayed Price · Currency is USD
3.100
0.00 (0.00%)
At close: Sep 16, 2026
PD-Rx Pharmaceuticals Ratios and Metrics
Market cap in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| 5 | 4 | 7 | 10 | 5 | 5 | |
Market Cap Growth | 10.32% | -39.75% | -33.34% | 84.59% | 9.38% | 9.20% |
Enterprise Value | -1 | -1 | -0 | 4 | 2 | 2 |
Last Close Price | 3.10 | 2.41 | 4.00 | 6.00 | 3.25 | 2.85 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
PE Ratio | - | - | - | - | 1.76 | 2.63 |
PS Ratio | 0.28 | 0.22 | 0.35 | 0.46 | 0.19 | 0.23 |
PB Ratio | 0.50 | 0.39 | 0.63 | 0.88 | 0.47 | 0.58 |
P/TBV Ratio | 0.50 | 0.39 | 0.63 | 0.88 | 0.47 | 0.58 |
P/FCF Ratio | 6.69 | 5.20 | - | 7.25 | 1.99 | - |
P/OCF Ratio | 6.66 | 5.18 | - | 5.52 | 1.65 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
EV/Sales Ratio | - | - | - | 0.21 | 0.09 | 0.11 |
EV/EBITDA Ratio | - | - | - | - | 0.59 | 2.39 |
EV/EBIT Ratio | - | - | - | - | 0.61 | 2.70 |
EV/FCF Ratio | - | - | - | 3.23 | 0.91 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Net Debt / Equity Ratio | -0.60 | -0.60 | -0.51 | -0.61 | -0.48 | -0.34 |
Net Debt / EBITDA Ratio | 18.80 | 18.80 | 6.76 | 132.90 | -1.32 | -2.93 |
Net Debt / FCF Ratio | -8.09 | -8.09 | 3.78 | -5.02 | -2.04 | 5.06 |
Asset Turnover | 1.49 | 1.49 | 1.47 | 1.63 | 2.38 | 2.19 |
Inventory Turnover | 6.41 | 6.41 | 6.88 | 8.37 | 7.87 | 6.51 |
Quick Ratio | 4.93 | 4.93 | 3.76 | 5.43 | 5.34 | 2.81 |
Current Ratio | 6.34 | 6.34 | 4.97 | 6.71 | 6.44 | 4.14 |
Return on Equity (ROE) | -2.48% | -2.48% | -6.93% | -0.87% | 30.59% | 24.57% |
Return on Assets (ROA) | -2.42% | -2.42% | -4.62% | -0.91% | 20.75% | 5.56% |
Return on Invested Capital (ROIC) | -10.41% | -10.41% | -20.01% | -3.70% | 52.33% | 18.11% |
Return on Capital Employed (ROCE) | -4.70% | -4.70% | -9.10% | -1.70% | 35.20% | 10.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Earnings Yield | -5.05% | -6.50% | -11.45% | -0.99% | 56.75% | 37.98% |
FCF Yield | 14.96% | 19.24% | -21.72% | 13.80% | 50.22% | -11.74% |
Buyback Yield / Dilution | 6.36% | 1.74% | -0.22% | 1.42% | 3.54% | 1.56% |